nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00498	0.00498	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.00478	0.00478	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00477	0.00477	CbGpPWpGaD
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—NOS2—abdominal aortic aneurysm	0.00474	0.00474	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.00466	0.00466	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—abdominal aortic aneurysm	0.00456	0.00456	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—abdominal aortic aneurysm	0.00453	0.00453	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—abdominal aortic aneurysm	0.00453	0.00453	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—abdominal aortic aneurysm	0.00452	0.00452	CbGpPWpGaD
Paroxetine—CHRM4—G alpha (i) signalling events—AGT—abdominal aortic aneurysm	0.0044	0.0044	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.0044	0.0044	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—AAAS—abdominal aortic aneurysm	0.00433	0.00433	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—SERPINE1—abdominal aortic aneurysm	0.00432	0.00432	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00424	0.00424	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—P2RY12—abdominal aortic aneurysm	0.00422	0.00422	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—P2RY12—abdominal aortic aneurysm	0.0042	0.0042	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—P2RY12—abdominal aortic aneurysm	0.00419	0.00419	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—P2RY12—abdominal aortic aneurysm	0.00414	0.00414	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.00411	0.00411	CbGpPWpGaD
Paroxetine—CYP2C9—Arachidonic acid metabolism—PTGS2—abdominal aortic aneurysm	0.00406	0.00406	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—abdominal aortic aneurysm	0.00406	0.00406	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—abdominal aortic aneurysm	0.00404	0.00404	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—abdominal aortic aneurysm	0.00403	0.00403	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—abdominal aortic aneurysm	0.00401	0.00401	CbGpPWpGaD
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—abdominal aortic aneurysm	0.00399	0.00399	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—AGTR1—abdominal aortic aneurysm	0.00394	0.00394	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—AGTR1—abdominal aortic aneurysm	0.00392	0.00392	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—AGTR1—abdominal aortic aneurysm	0.0039	0.0039	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—AGTR1—abdominal aortic aneurysm	0.00387	0.00387	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—AAAS—abdominal aortic aneurysm	0.00384	0.00384	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00379	0.00379	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.00377	0.00377	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00363	0.00363	CbGpPWpGaD
Paroxetine—HTR2A—G alpha (q) signalling events—AGT—abdominal aortic aneurysm	0.00358	0.00358	CbGpPWpGaD
Paroxetine—CHRM1—G alpha (q) signalling events—AGT—abdominal aortic aneurysm	0.00356	0.00356	CbGpPWpGaD
Paroxetine—CHRM3—G alpha (q) signalling events—AGT—abdominal aortic aneurysm	0.00355	0.00355	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00352	0.00352	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.0035	0.0035	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00337	0.00337	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00337	0.00337	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00336	0.00336	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.00335	0.00335	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00334	0.00334	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.00333	0.00333	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00331	0.00331	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.00328	0.00328	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—abdominal aortic aneurysm	0.00321	0.00321	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.0032	0.0032	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—abdominal aortic aneurysm	0.00319	0.00319	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—abdominal aortic aneurysm	0.00318	0.00318	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.00312	0.00312	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—NOS2—abdominal aortic aneurysm	0.00307	0.00307	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.00306	0.00306	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.00298	0.00298	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—AGT—abdominal aortic aneurysm	0.00293	0.00293	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00288	0.00288	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00276	0.00276	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.00267	0.00267	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—SERPINE1—abdominal aortic aneurysm	0.00259	0.00259	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00257	0.00257	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00255	0.00255	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.00255	0.00255	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00255	0.00255	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00252	0.00252	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.0025	0.0025	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.00245	0.00245	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—NFKB1—abdominal aortic aneurysm	0.00241	0.00241	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00239	0.00239	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.00237	0.00237	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00237	0.00237	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—NFKB1—abdominal aortic aneurysm	0.00237	0.00237	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00237	0.00237	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.00236	0.00236	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.00235	0.00235	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00234	0.00234	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.00233	0.00233	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.00223	0.00223	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.0022	0.0022	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.00217	0.00217	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.00215	0.00215	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.00215	0.00215	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.00214	0.00214	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.00213	0.00213	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.0021	0.0021	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.00205	0.00205	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00202	0.00202	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	0.00201	0.00201	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00195	0.00195	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00194	0.00194	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00194	0.00194	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00194	0.00194	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00193	0.00193	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00192	0.00192	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—AAAS—abdominal aortic aneurysm	0.00191	0.00191	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.00189	0.00189	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00186	0.00186	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.00181	0.00181	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.00181	0.00181	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.0018	0.0018	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.00179	0.00179	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.00177	0.00177	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AGT—abdominal aortic aneurysm	0.00176	0.00176	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.00173	0.00173	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—APOE—abdominal aortic aneurysm	0.00172	0.00172	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.00166	0.00166	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	0.00164	0.00164	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.00153	0.00153	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.00151	0.00151	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.00149	0.00149	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—abdominal aortic aneurysm	0.00149	0.00149	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.00148	0.00148	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.00148	0.00148	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.00146	0.00146	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.00146	0.00146	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.00145	0.00145	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.00145	0.00145	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.00144	0.00144	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.00144	0.00144	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.00144	0.00144	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.00143	0.00143	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.00143	0.00143	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AAAS—abdominal aortic aneurysm	0.00141	0.00141	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.00137	0.00137	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.00137	0.00137	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00137	0.00137	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00136	0.00136	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00136	0.00136	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.00135	0.00135	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00134	0.00134	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00132	0.00132	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00131	0.00131	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.00131	0.00131	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00131	0.00131	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00129	0.00129	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—abdominal aortic aneurysm	0.00129	0.00129	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.00128	0.00128	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.00127	0.00127	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.00127	0.00127	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.00126	0.00126	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—LDLR—abdominal aortic aneurysm	0.00123	0.00123	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AAAS—abdominal aortic aneurysm	0.00121	0.00121	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.00117	0.00117	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.00117	0.00117	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.00116	0.00116	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.00115	0.00115	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.00115	0.00115	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.00113	0.00113	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.0011	0.0011	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.00108	0.00108	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	0.00106	0.00106	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—LDLR—abdominal aortic aneurysm	0.00106	0.00106	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	0.00104	0.00104	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.00104	0.00104	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.00104	0.00104	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.00103	0.00103	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.00103	0.00103	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.00103	0.00103	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AAAS—abdominal aortic aneurysm	0.00103	0.00103	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.00102	0.00102	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.00102	0.00102	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.00102	0.00102	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.00102	0.00102	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.00101	0.00101	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.001	0.001	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.00098	0.00098	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.00097	0.00097	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000965	0.000965	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000962	0.000962	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000952	0.000952	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.000928	0.000928	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.000923	0.000923	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.00092	0.00092	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.000911	0.000911	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—LDLR—abdominal aortic aneurysm	0.000895	0.000895	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AAAS—abdominal aortic aneurysm	0.000894	0.000894	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	0.000865	0.000865	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	0.000847	0.000847	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AAAS—abdominal aortic aneurysm	0.000842	0.000842	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AAAS—abdominal aortic aneurysm	0.000835	0.000835	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000808	0.000808	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000792	0.000792	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—LDLR—abdominal aortic aneurysm	0.00078	0.00078	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000779	0.000779	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000775	0.000775	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000774	0.000774	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000772	0.000772	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000765	0.000765	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.000764	0.000764	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.00076	0.00076	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000758	0.000758	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.000757	0.000757	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.00075	0.00075	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—LDLR—abdominal aortic aneurysm	0.000735	0.000735	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—LDLR—abdominal aortic aneurysm	0.000729	0.000729	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—abdominal aortic aneurysm	0.000713	0.000713	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000694	0.000694	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.00069	0.00069	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000688	0.000688	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000681	0.000681	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000666	0.000666	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AGT—abdominal aortic aneurysm	0.00065	0.00065	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000638	0.000638	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—APOE—abdominal aortic aneurysm	0.000637	0.000637	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.000621	0.000621	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.000595	0.000595	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—abdominal aortic aneurysm	0.000581	0.000581	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AGT—abdominal aortic aneurysm	0.000559	0.000559	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000548	0.000548	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOE—abdominal aortic aneurysm	0.000548	0.000548	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000545	0.000545	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000543	0.000543	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000538	0.000538	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000537	0.000537	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000534	0.000534	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000532	0.000532	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000527	0.000527	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000476	0.000476	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AGT—abdominal aortic aneurysm	0.000473	0.000473	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.000471	0.000471	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOE—abdominal aortic aneurysm	0.000464	0.000464	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000456	0.000456	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000451	0.000451	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.000451	0.000451	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000449	0.000449	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000447	0.000447	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000443	0.000443	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—abdominal aortic aneurysm	0.000436	0.000436	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.000421	0.000421	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.000419	0.000419	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.000418	0.000418	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.000414	0.000414	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AGT—abdominal aortic aneurysm	0.000412	0.000412	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOE—abdominal aortic aneurysm	0.000404	0.000404	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AGT—abdominal aortic aneurysm	0.000389	0.000389	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AGT—abdominal aortic aneurysm	0.000385	0.000385	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOE—abdominal aortic aneurysm	0.000381	0.000381	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOE—abdominal aortic aneurysm	0.000377	0.000377	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—abdominal aortic aneurysm	0.000375	0.000375	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000323	0.000323	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000321	0.000321	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.00032	0.00032	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.000319	0.000319	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—abdominal aortic aneurysm	0.000318	0.000318	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.000318	0.000318	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000317	0.000317	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.000317	0.000317	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.000314	0.000314	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—abdominal aortic aneurysm	0.000277	0.000277	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—abdominal aortic aneurysm	0.000261	0.000261	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—abdominal aortic aneurysm	0.000259	0.000259	CbGpPWpGaD
